Xovoltib 20 mg contains Afatinib, which is a targeted cancer therapy used primarily to treat non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR) gene. Afatinib is classified as a tyrosine kinase inhibitor (TKI), and it works by inhibiting the activity of proteins involved in the growth and spread of cancer cells.

Common Uses Xovoltib 20 Mg :

1. Non-Small Cell Lung Cancer (NSCLC): Xovoltib is primarily used to treat patients with NSCLC whose tumors have specific EGFR mutations. It is often prescribed as first-line therapy in such cases.
2. EGFR Mutation-Positive Tumors: It is especially effective in patients whose tumors have exon 19 deletions or exon 21 (L858R) substitution mutations.